Fierce Pharma

DECEMBER 4, 2023

Fujifilm Corporation is spreading the wealth across two production units as the contract development and manufacturing organization (CDMO) juggernaut works through a cell therapy expansion. | Fujifilm is dividing $200 million between a pair of subsidiaries. Those are: Fujifilm Cellular Dynamics, which specializes in development and manufacturing of human induced pluripotent stem cells (iPSC), and the organization’s CDMO for biologics and advanced therapies, Fujifilm Diosynth Biotechnologies.

Specialization 261

Specialization Manufacturing 261

MedCity News

DECEMBER 4, 2023

Roche’s Carmot Therapeutics acquisition brings three clinical-stage assets that the companies say could be best-in-class drugs for metabolic disorders. In addition to standalone use, Roche sees the Carmot molecules as part of potential combinations with its own drug candidates.

Biopharma 110

Biopharma Pharma 110

Fierce Pharma

DECEMBER 4, 2023

A challenging year for the biotech industry has taken a heavy toll on Chinese manufacturer WuXi Biologics, sending the company’s stock plummeting nearly 24% Monday. | WuXi Biologics expects to miss its original sales target for the year by around $400 million, thanks to reductions across its development and manufacturing services. WuXi blamed the projected miss largely on a COVID-related revenue slowdown and a decline in projects.

Manufacturing 244

Manufacturing Sales 244

MedCity News

DECEMBER 4, 2023

As providers look to find more stability as they pivot into VBC waters, they need to be conscious of the partnerships they forge on this journey. Done correctly, the right collaborative approach can have significant positive downstream impacts for all of a practice’s patients – even the ones not currently in a VBC plan.

Patients 110

Patients 110

Advertisement

Distribution

Fierce Pharma

DECEMBER 4, 2023

South Africa’s Aspen Pharmacare is growing its global footprint with a new agreement, worth up to 92.6 million euros ($100.3 million), to buy Sandoz’s China operations. | The move is expected to bring in some $95 million in annual sales, the company said. In a separate deal, Sandoz snapped up four Aspen products for $60 million.

Sales 161

Sales 161

MedCity News

DECEMBER 4, 2023

Rising out-of-pocket costs and barriers preventing or delaying the utilization of healthcare coverage highlight the need for a comprehensive approach that goes beyond insurance coverage alone and addresses the underlying issues affecting healthcare accessibility and affordability.

Insurance 107

Insurance Healthcare Healthcare 107

MedCity News

DECEMBER 4, 2023

A new partnership between Aledade and Anthem Blue Cross and Blue Shield in Virginia aims to improve access to value-based primary care for Medicaid members.

114

114

pharmaphorum

DECEMBER 4, 2023

Roche has agreed a deal to acquire US biotech Carmot Therapeutics that if consummated will thrust it into the increasingly competitive market for incretin-based therapies for diabetes and obesity. The Swiss pharma group has agreed to pay $2.7 billion upfront in cash when the deal closes, with shareholders in the US company also in line for up to $400 million if the drug programmes covered by the agreement meet various milestones.

Competition 99

Competition Pharma Marketing 99

MedCity News

DECEMBER 4, 2023

To create the Golden Age of Healthcare Delivery, we need to understand healthcare workers’ pain points, personalize systems, and make information systems work for them, to ensure that the Golden Age of Medicine is fully realized for all in every community.

Healthcare 105

Healthcare Healthcare Medicine 105

European Pharmaceutical Review

DECEMBER 4, 2023

The European Commission (EC ) has authorised ZILBRYSQ ® (zilucoplan)▼ as the first once-daily subcutaneous (SC), targeted peptide inhibitor of complement component 5 (C5) inhibitor for generalised myasthenia gravis ( gMG ). It is also the only C5 inhibitor approved for self-administration by adult patients who are AChR antibody-positive with this disease.

Medicine 98

Medicine Patients Pharmaceutical 98

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

MedCity News

DECEMBER 4, 2023

It’s easy to get caught up in the excitement surrounding innovations in the medical field, Amazon Pharmacy Chief Medical Officer Dr. Vin Gupta noted. But when talking about these innovations, healthcare leaders often fail to address questions about whether they will be covered by insurance and whether all patients will be able to benefit from them, he pointed out.

Insurance 102

Insurance Medical Healthcare Healthcare 102

European Pharmaceutical Review

DECEMBER 4, 2023

The (bio)pharmaceutical industry is currently facing numerous hurdles in its path to high-efficiency production that are more complex and pressing than ever before. One of the most significant perceived challenges is the ability to implement new innovations and increase productivity while adhering to stringent regulatory demands. The race to develop new drugs and therapies demands rapid drug discovery, testing and time-to-market.

Pharmaceutical manufacturing 92

Pharmaceutical manufacturing Manufacturing Pharmaceutical Pharmaceutical products 92

MedCity News

DECEMBER 4, 2023

A new guide from Northeast Business Group on Health helps employers understand the challenges women face when it comes to cardiovascular disease, diabetes and obesity. It also recommends actions that employers can take to support women in their workforce.

97

97

European Pharmaceutical Review

DECEMBER 4, 2023

A report published by MarketsandMarkets has estimated that the pharmaceutical excipients market will value $14.9 billion by 2028, growing at a CAGR of 6.8 percent between 2023 to 2028. This is compared to the expected revenue for the market in 2023 reaching $10.7 billion. Excipients market opportunities and limitations Major contributing factors regarding growth of the pharmaceutical excipients market are: increasing demand for generic drugs and drug products, increased investment in R&D for

Marketing 92

Marketing Pharmaceutical Manufacturing Medicine 92

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

MedCity News

DECEMBER 4, 2023

Eli Lilly’s Jaypirca is now approved for treating three types of blood cancers. While Jaypirca blocks a target already addressed by other cancer therapies, the Lilly molecule does it in a way that sets it apart from the rest of its drug class.

FDA 93

FDA Biopharma Pharma 93

PharmaVoice

DECEMBER 4, 2023

Market expectations for obesity drugs are soaring and competition is heating up. But hitting the heights will require overcoming payer and other issues.

Marketing 98

Marketing Competition 98

MedCity News

DECEMBER 4, 2023

As we embark on the winter season, the significance of respiratory health becomes even more pronounced. The challenges posed by cold weather, compounded by air pollution, necessitate a proactive approach.

90

90

PharmaVoice

DECEMBER 4, 2023

AstraZeneca’s Gemma Satterthwaite talks to the company’s ambition to transform the entire care experience for patients with blood cancers.

Patients 98

Patients 98

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

Copyright Clearance Center

DECEMBER 4, 2023

We asked the Chefs for their thoughts on the Biden Administration's Executive Order on “Safe, Secure, and Trustworthy Artificial Intelligence.

98

98

Pharmaceutical Commerce

DECEMBER 4, 2023

Critical factors need to be addressed for pharma stakeholders to realize the full potential of generative artificial intelligence.

Healthcare 102

Healthcare Healthcare Pharma 102

Pharmaceutical Technology

DECEMBER 4, 2023

Eli Lilly has received approval from the US FDA for Jaypirca to treat chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL)

FDA 96

FDA 96

PharmaTimes

DECEMBER 4, 2023

In England, an estimated 4,500 people are living with undiagnosed HIV - News - PharmaTimes

114

114

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

Pharmaceutical Technology

DECEMBER 4, 2023

Roche has signed an agreement for the acquisition of US-based company Carmot Therapeutics in a deal valued at $2.7bn, to be paid in cash.

98

98

PharmaTimes

DECEMBER 4, 2023

The neurological condition affects around 50 million people worldwide - News - PharmaTimes

96

96

Pharmaceutical Technology

DECEMBER 4, 2023

The US Food and Drug Administration (FDA) has granted approval for Ambio’s generic version of Forteo for the treatment of osteoporosis.

Food and Drug Administration 98

Food and Drug Administration FDA Food 98

pharmaphorum

DECEMBER 4, 2023

Undiagnosed dementia in UK needs drastic action, says review Phil.

99

99

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Pharmaceutical Technology

DECEMBER 4, 2023

The agreement allows Guardant Health to leverage Cancer Research UK’s network to validate its technologies.

Networking 97

Networking 97

pharmaphorum

DECEMBER 4, 2023

AstraZeneca links with Absci on AI for biologics discovery Phil.

88

88

Pharmaceutical Technology

DECEMBER 4, 2023

The $247m deal will focus on the use of generative artificial intelligence to develop an antibody therapy for an unnamed cancer.

64

64

Contrarian Sales Techniques

DECEMBER 4, 2023

In the bustling world of pharmaceutical sales, the role of a sample bag is often understated yet crucial. Imagine this: a pharmaceutical sales representative, armed with the latest and greatest in medical advancements, sets out to make their mark in the competitive healthcare industry. The sample bag they carry isn’t just a container. It’s a mobile showcase, a silent yet persuasive partner in every pitch and presentation.

Sales 52

Sales Pharmaceutical Sales Pharma Ethics 52

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management